PRINCETON, N.J., Feb. 7 /PRNewswire-FirstCall/ -- Pharmacopeia , an innovator in the discovery and development of novel small molecule therapeutics, today announced that the company plans to release its financial results for the fourth quarter and full year ended December 31, 2006 after the close of market on Wednesday, February 21, 2007. The company will conduct a webcast and conference call at 5:00 p.m. EST on the same day.
Dr. Leslie J. Browne, President and Chief Executive Officer, Mr. Brian M. Posner, Executive Vice President and Chief Financial Officer, and Dr. Rene Belder, Vice President, Clinical and Regulatory Affairs will host the call. Forward-looking and other material information may be discussed on this conference call.
Date: February 21, 2007 Time: 5:00 p.m. EST Webcast: Accessible via the Company's website at http://www.pharmacopeia.com Domestic callers: (800) 967-7135 International callers: (719) 457-2626 Confirmation code: 6571437 Name of conference: Pharmacopeia Fourth Quarter and Full-Year 2006 Financial Results
A replay of the conference call can be accessed by dialing toll-free (888) 203-1112 in the U.S., or (719) 457-0820 outside the U.S. The access code for the replay is 6571437. Replay of the webcast will also be accessible on Pharmacopeia's website on the Investors page at http://www.pharmacopeia.com. The replays will be available for two weeks.
ABOUT PHARMACOPEIA
Pharmacopeia is committed to discovering and developing novel therapeutics to address significant medical needs. The Company has a broad portfolio advancing towards clinical validation, both independently and with partners. Pharmacopeia's most advanced internal program is a dual-acting angiotensin and endothelin receptor antagonist (DARA) for resistant hypertension and diabetic kidney disease for which the IND has been submitted. Other internal proprietary programs address immunoregulation. Three partnered programs are in active clinical trials: a CXCR2 antagonist for chronic obstructive pulmonary disease (COPD), p38 MAP kinase inhibitors for rheumatoid arthritis, and an enzyme inhibitor for oncology. Six additional partnered compounds are in preclinical development. Pharmacopeia's discovery, development and commercialization partnerships are with leading pharmaceutical companies including GlaxoSmithKline, Bristol-Myers Squibb, Organon, Schering-Plough, Cephalon, Celgene, and Wyeth.
Contact: Amy P. Sharpless (609) 452-3643 irreq@pcop.com
This press release, and oral statements made with respect to information contained in this press release, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those which express plan, anticipation, intent, contingency or future development and/or otherwise are not statements of historical fact. These statements are based upon management's current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. Further information about these and other relevant risks and uncertainties may be found in Pharmacopeia's Reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Pharmacopeia urges you to carefully review and consider the disclosures found in its filings which are available in the SEC EDGAR database at http://www.sec.gov and from Pharmacopeia at http://www.pharmacopeia.com. All forward-looking statements in this press release and oral statements made with respect to information contained in this press release are qualified entirely by the cautionary statements included in this press release and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by such forward-looking statements. These forward-looking statements speak only as of the date of this press release. Pharmacopeia undertakes no obligation to (and expressly disclaims any such obligation to) publicly update or revise the statements made herein or the risk factors that may relate thereto whether as a result of new information, future events, or otherwise.
Pharmacopeia Drug Discovery, Inc.CONTACT: Amy P. Sharpless, Pharmacopeia Drug Discovery, +1-609-452-3643,irreq@pcop.com
Web site: http://www.pharmacopeia.com/
